Cargando…

Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis

OBJECTIVES: While cardiac amyloidosis (CA) classically involves the left ventricle (LV), less is known about its impact on the right ventricle (RV) and pulmonary vasculature. We performed a retrospective analysis to identify the prevalence and types of pulmonary hypertension (PH) profiles in CA and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Slivnick, Jeremy, Zareba, Karolina M, Varghese, Juliet, Truong, Vien, Wallner, Alexander L, Tong, Matthew S, Hummel, Christopher, Mazur, Wojciech, Rajpal, Saurabh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Pulmonary Vascular Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900043/ https://www.ncbi.nlm.nih.gov/pubmed/35246499 http://dx.doi.org/10.1136/openhrt-2021-001808

Ejemplares similares

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy
por: Ghio, Stefano, et al.
Publicado: (2016)

Indexed left ventricular mass to QRS voltage ratio is associated with heart failure hospitalizations in patients with cardiac amyloidosis
por: Slivnick, Jeremy A., et al.
Publicado: (2020)

Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study
por: Palmer, Cassady, et al.
Publicado: (2022)

Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Fukui, Shigefumi, et al.
Publicado: (2016)

Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension
por: Han, Yuchi, et al.
Publicado: (2018)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

COVID-19 AS A PRIMARY CAUSE OF PULMONARY ARTERIAL HYPERTENSION
por: RAVAL, ABHIJIT, et al.
Publicado: (2021)

Prevalence of pulmonary hypertension in mitral regurgitation and its influence on outcomes
por: Ratwatte, Seshika, et al.
Publicado: (2023)

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
por: Pagnesi, Matteo, et al.
Publicado: (2020)

Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response
por: Goh, Ze Ming, et al.
Publicado: (2022)

Right heart function during simulated altitude in patients with pulmonary arterial hypertension
por: Seccombe, Leigh M, et al.
Publicado: (2017)

Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension
por: Chouvarine, Philippe, et al.
Publicado: (2020)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension
por: Suzuki, Sho, et al.
Publicado: (2022)

Continuous long-term heart rate variability and risk assessment in pulmonary hypertension
por: Andersen, Mads Ørbæk, et al.
Publicado: (2023)

Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial
por: Russell, Stuart, et al.
Publicado: (2019)

Prognostic relevance of the right ventricular myo-mechanical index (RV-MMI) in patients with precapillary pulmonary hypertension
por: Greiner, Sebastian, et al.
Publicado: (2018)

Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland
por: Stubbs, Harrison, et al.
Publicado: (2022)

Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review
por: Varela, Daniel L, et al.
Publicado: (2018)

Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study
por: Gerhardt, Felix, et al.
Publicado: (2017)

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines
por: Dardi, Fabio, et al.
Publicado: (2021)

Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry
por: Minatsuki, Shun, et al.
Publicado: (2021)

Impairment in quantitative microvascular function in non-ischemic cardiomyopathy as demonstrated using cardiovascular magnetic resonance
por: Slivnick, Jeremy A., et al.
Publicado: (2022)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper
por: Abraham, Paul, et al.
Publicado: (2018)

Mechanisms of ECG signs in chronic obstructive pulmonary disease
por: Larssen, Marte Strømsnes, et al.
Publicado: (2017)

CENTRAL AND PERIPHERAL VENOUS THROMBOSIS IN NON-MECHANICALLY VENTILATED SURVIVORS OF COVID-19
por: Nauka, Peter, et al.
Publicado: (2020)

ACUTE PULMONARY EMBOLISM AND MYOCARDIAL INJURY IN COVID-19 PATIENT
por: Alfaki, Musaab, et al.
Publicado: (2020)

ANTICOAGULATION AND COVID-19: A META-ANALYSIS
por: Ho, Kam Sing, et al.
Publicado: (2020)

PULMONARY EMBOLISM AND RIGHT HEART STRAIN PATTERN IN COVID-19: AN INCIDENTAL FINDING OR A PERSISTENT PATTERN?
por: Roomi, Sohaib, et al.
Publicado: (2020)

PHLEGMASIA CERULEA DOLENS: AN ATYPICAL COVID-19 PRESENTATION
por: Akkari, Riad, et al.
Publicado: (2020)

MASSIVE PULMONARY EMBOLISM TREATED WITH THROMBOLYSIS IN COVID-19: A CASE SERIES
por: Alarcon-Calderon, Amarilys, et al.
Publicado: (2020)

COVID-19-ASSOCIATED COAGULOPATHY AS A PRESENTATION OF CORONAVIRUS DISEASE 2019: A PATIENT PRESENTS WITH A LARGE STROKE, PULMONARY EMBOLISM, AND DVT
por: Ramanathan, Rudra, et al.
Publicado: (2020)

Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase
por: DiNicolantonio, James J, et al.
Publicado: (2020)

SADDLE PULMONARY EMBOLISM WITH CRITICAL LIMB ISCHEMIA IN COVID-19
por: MAHGOUB, AHMED, et al.
Publicado: (2021)

UTILITY OF D-DIMER CUT-OFF POINT WITH VTE IN CRITICALLY ILL PATIENTS WITH COVID-19
por: ZHANG, RAINY, et al.
Publicado: (2021)

THROMOEMBOLIC DISEASE: ONE OF MANY COMMON POST-COVID-19 COMPLICATIONS COMING SOON TO AN EMERGENCY ROOM NEAR YOU
por: BAIRD, ANDREW, et al.
Publicado: (2021)

CASE REPORT OF A COVID-19 INFECTION AND THROMBOEMBOLISM IN A PATIENT WITH ULCERATIVE COLITIS ON TOFACITINIB
por: SOMPALLI, SREEJA, et al.
Publicado: (2021)

SICKLE CELL DISEASE AND COVID-19
por: HANNA, SANDRINE, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_niq79q6abqohha3gbvluaqmq87